Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Loss of p27Kip1 cooperates with cyclin E in T-cell lymphomagenesis

Oncogene volume 22, pages 1724–1729 (2003)Cite this article

Abstract

Cyclin E and p27Kip1 are key regulators for cyclin-dependent kinases (Cdks) acting at the G1-/S-phase transition of the cell cycle. Whereas cyclin E is required for the activation of Cdk2, p27Kip1 is a specific Cdk inhibitor and can block cell division. High levels of cyclin E and low levels of p27Kip1 expression have been associated with malignant lymphomas in humans; the level of p27Kip1 is even considered of prognostic significance. However, mice that lack p27Kip1 do not develop any malignant lymphomas despite a pronounced lymphoid hyperplasia in thymus and spleen. We have previously described transgenic mice that carry a construct in which the cyclin E cDNA is under the control of the CD2 promoter/enhancer region and thus express high levels of cyclin E in the T-cell compartment (CD2-cyclin E). These animals are not predisposed for T-cell lymphomas in the absence of other cooperating events. Here we show that T-cells from CD2-cyclin E mice that at the same time are deficient for p27Kip1 show a significantly higher Cdk2 activity than cells from wilde-type or single mutant animals. Accordingly, a higher percentage of T cells in S/G2/M phase is found in CD2-cyclin E/p27Kip1−/− mice. After a long latency period of over 200 days, these animals develop spontaneous monoclonal T cell lymphoma whereas none of the single CD2-cyclin E transgenics or the p27Kip1-deficient mice showed any sign of lymphoid malignancies. Our findings demonstrate that a deregulation of control mechanisms at the G1/S transition by the combination of high cyclin E levels in the absence of p27Kip1 is sufficient to predispose mice to develop lymphoid malignancies and further support a role of p27Kip1 as a tumor suppressor and of cyclin E as a dominant oncogene.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Bartek J, Bartkova J and Lukas J . (1996). Curr. Opin. Cell Biol., 8, 805–914.

  • Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW and Adams JM . (1994) EMBO J., 13, 2124–2130.

  • Bortner DM and Rosenberg MP . (1997). Mol. Cell. Biol., 17, 453–459.

  • Deng C, Zhang P, Harper JW, Elledge SJ and Leder P . (1995). Cell, 82, 675–684.

  • Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C and Pandolfi PP . (2001). Nat. Genet., 27, 222–224.

  • Donnellan R and Chetty R . (1999). FASEB J., 13, 773–780.

  • Erlanson M and Landberg G . (2001). Leukemia Lymphoma, 40, 461–470.

  • Erlanson M, Portin C, Linderholm B, Lindh J, Roos G and Landberg G . (1998). Blood, 92, 770–777.

  • Fero ML, Randel E, Gurley KE, Roberts JM and Kemp CJ . (1998). Nature, 396, 177–180.

  • Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K and Roberts JM . (1996). Cell, 85, 733–744.

  • Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M and Beach D . (1995). Science, 269, 1575–1577.

  • Geisen C and Möröy T . (2002). J. Biol. Chem., 277, 39909–39918.

  • Haas K, Johannes C, Geisen C, Schmidt T, Karsunky H, Blass-Kampmann S, Obe G and Möröy T . (1997a). Oncogene, 15, 2615–2623.

  • Haas K, Staller P, Geisen C, Bartek J, Eilers M and Möröy T . (1997b). Oncogene, 15, 179–192.

  • Hall M, Bates S and Peters G . (1995). Oncogene, 11, 1581–1588.

  • Hall M and Peters G . (1996). Adv. Cancer Res., 68, 67–108.

  • Hanahan D and Weinberg RA . (2000). Cell, 100, 57–70.

  • Harper JW and Elledge SJ . (1996). Curr. Opin. Genet. Dev., 6, 56–64.

  • Hogan B, Beddington R, Costantini F and Lacy E . (1994). Manipulating the Mouse Embryo. CSH-Laboratory Press, New York, USA.

    Google Scholar 

  • Hwang HC, Martins CP, Bronkhorst Y, Randel E, Berns A, Fero M and Clurman BE . (2002). Proc. Natl. Acad. Sci. USA, 99, 11293–11298.

  • Karsunky H, Geisen C, Schmidt T, Haas K, Zevnik B, Gau E and Möröy T . (1999). Oncogene 18, 7816–8274.

  • Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A . (1996). Cell 85, 721–732.

  • Lovec H, Grzeschiczek A, Kowalski MB and Möröy T . (1994a). EMBO J., 13, 3487–3495.

  • Lovec H, Sewing A, Lucibello FC, Müller R and Möröy T . (1994b). Oncogene, 9, 323–326.

  • Lüscher B . (2001). Gene, 277, 1–14.

  • Martins CP and Berns A . (2002). EMBO J., 21, 3739–3748.

  • Minella AC, Swanger J, Bryant E, Welcker M, Hwang H and Clurman BE . (2002). Curr. Biol., 12, 1817–1827.

  • Morgan DO . (1995). Nature, 374, 131–134.

  • Möröy T, Fisher P, Guidos C, Ma A, Zimmerman K, Tesfaye A, DePinho R, Weissman I and Alt FW . (1990). EMBO J., 9, 3659–3666.

  • Möröy T, Grzeschiczek A, Petzold S and Hartmann KU . (1993). Proc. Natl. Acad. Sci. USA, 90, 10734–10738.

  • Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K . (1996). Cell, 85, 707–720.

  • Planas-Silva MD and Weinberg RA . (1997). Curr. Opin. Cell Biol., 9, 768–772.

  • Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A . (1994). Genes Dev., 8, 9–22.

  • Reynisdottir I, Polyak K, Iavarone A and Massague J . (1995). Genes Dev., 9, 1831–1845.

  • Ruas M Peters G . (1998). Biochim. Biophys. Acta, 1378, F115–F177.

  • Sambrook J, Fritsch EF and Maniatis T . (1989). Molecular Cloning – A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA.

    Google Scholar 

  • Sherr CJ . (1996). Science, 274, 1672–1677.

  • Sherr CJ and Roberts JM . (1995). Genes Dev., 9, 1149–1163.

  • Slingerland J and Pagano M . (2000). J. Cell Physiol., 183, 10–17.

  • Weinberg RA . (1996). Cell, 85, 457–459.

Download references

Acknowledgements

This work was supported by grants of the Deutsche Forschungsgemeinschaft (Mo 435/11-1) and the Dr Mildred Scheel Stiftung für Krebsforschung and the Fonds der chemischen Industrie.

Author information

Author notes

  1. Christoph Geisen

    Present address: The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA

  2. Holger Karsunky

    Present address: Stanford University, School of Medicine, Stanford, CA, 94305-5329, USA

  3. Contributed equally to this paper

Authors and Affiliations

  1. Institut für Zellbiologie (Tumorforschung), I F Z, Universitätsklinikum Essen, Virchowstrasse 173, Essen, D-45122, Germany

    Christoph Geisen, Holger Karsunky, Raif Yücel & Tarik Möröy

Authors
  1. Christoph Geisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holger Karsunky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raif Yücel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tarik Möröy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tarik Möröy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geisen, C., Karsunky, H., Yücel, R. et al. Loss of p27Kip1 cooperates with cyclin E in T-cell lymphomagenesis. Oncogene 22, 1724–1729 (2003). https://doi.org/10.1038/sj.onc.1206340

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206340

Keywords

This article is cited by

Search

Advanced search

Quick links